|
|
 |
|
Viewing report
|
|
|
|
Merck KGaA: Pipeline, Products, Performance and Potential
Espicom Business Intelligence Ltd, June 2009, Pages: 144
With a tradition of over three hundred years, Merck KGaA is one of the oldest pharmaceutical and chemical companies in the world. Merck has 192 companies in 60 countries, which employ over 30,000 personnel worldwide. Merck has focused its corporate headquarters and research & development in Darmstadt, Germany. However, it also operates important research sites in France, Spain, Switzerland, the UK, the US and Japan.
Merck’s pharmaceutical operations are divided into the Merck Serono business and Consumer Health Care. For the former, research and marketing efforts are centred on two key therapeutic areas, namely Oncology and Neurology.
Integration of Serono into what was previously the Ethicals Division to form Merck Serono was completed in September 2007. The acquisition took place in January 2007 and the merger created a combined business with strong capabilities, especially in neurology and oncology. Together with Serono, this segment of Merck achieves:
- critical mass in research and development with an annual budget of approximately EUR 1 billion;
- R&D capabilities greater than the sum of the parts;
- a market-leading multiple sclerosis franchise broaden its business portfolio;
- an expanded geographic reach and access to the US market; and
- world-class biotechnology manufacturing.
The headquarters of this business remain in Geneva, Switzerland. Merck-Serono Biopharmaceuticals’ US headquarters are in Boston, MA.
Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.
Customers who bought this item also bought
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
Pfizer: Pipeline, Products, Performance, Potential
Prescription Drugs - Global Strategic Business Report
Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
The Neurology Pipeline: A Strategic Review
What to Do When the R&D Pipeline Runs Dry
Licensing Opportunities: Neurology
Competitor Analysis - Cancer Antibodies in Early Clinical Development
Value-Added Pharma: How to Accomplish the Impossible
Neurological Disease: Early-Stage R&D and Dealmaking
|
|
|
|
